JHCP
ABBV icon

Jackson Hole Capital Partners’s AbbVie ABBV Stock Holding History

Jackson Hole Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.81M Buy
35,906
+601
+2% +$133K 1.29% 16
2025
Q4 		$8.07M Sell
35,305
-36
-0.1% -$8.2K 1.38% 15
2025
Q3 		$8.18M Sell
35,341
-423
-1% -$86.1K 1.4% 14
2025
Q2 		$6.64M Buy
35,764
+253
+0.7% +$47K 1.22% 17
2025
Q1 		$7.44M Sell
35,511
-436
-1% -$84.8K 1.48% 12
2024
Q4 		$6.39M Buy
35,947
+1,797
+5% +$330K 1.29% 17
2024
Q3 		$6.74M Hold
34,150
– – 1.41% 14
2024
Q2 		$5.86M Buy
34,150
+1,890
+6% +$313K 1.27% 18
2024
Q1 		$5.87M Sell
32,260
-1,872
-5% -$323K 1.32% 17
2023
Q4 		$5.29M Buy
34,132
+1,749
+5% +$255K 1.35% 14
2023
Q3 		$4.83M Sell
32,383
-1,005
-3% -$148K 1.41% 14
2023
Q2 		$4.5M Buy
33,388
+304
+0.9% +$44.6K 1.23% 17
2023
Q1 		$5.27M Sell
33,084
-641
-2% -$98K 1.38% 13
2022
Q4 		$5.45M Sell
33,725
-275
-0.8% -$42.2K 1.63% 13
2022
Q3 		$4.56M Buy
34,000
+587
+2% +$84.2K 1.4% 14
2022
Q2 		$5.12M Buy
33,413
+90
+0.3% +$13.8K 1.6% 11
2022
Q1 		$5.4M Sell
33,323
-262
-0.8% -$38.1K 1.56% 12
2021
Q4 		$4.55M Buy
33,585
+1,974
+6% +$233K 1.42% 15
2021
Q3 		$3.41M Buy
31,611
+4,775
+18% +$546K 1.11% 23
2021
Q2 		$3.02M Buy
26,836
+4,291
+19% +$483K 1.05% 25
2021
Q1 		$2.44M Buy
22,545
+3,718
+20% +$398K 1% 26
2020
Q4 		$2.02M Buy
18,827
+774
+4% +$74.4K 0.92% 35
2020
Q3 		$1.58M Buy
18,053
+429
+2% +$40.4K 0.83% 37
2020
Q2 		$1.73M Buy
17,624
+513
+3% +$45.2K 1.05% 28
2020
Q1 		$1.3M Buy
17,111
+1,972
+13% +$168K 0.97% 33
2019
Q4 		$1.34M Hold
15,139
– – 0.74% 39
2019
Q3 		$1.15M Buy
15,139
+5,508
+57% +$378K 0.65% 44
2019
Q2 		$700K Buy
9,631
+2,921
+44% +$230K 0.43% 62
2019
Q1 		$541K Buy
6,710
+623
+10% +$51K 0.48% 73
2018
Q4 		$561K Buy
+6,087
New +$535K 0.59% 58

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jackson Hole Capital Partners's ABBV Position: Q1 2026 in Review

Jackson Hole Capital Partners increased its AbbVie (ABBV) stake by 1.7% in Q1 2026, buying an estimated $133K and bringing the position to 35,906 shares worth $7.81M. The position accounts for 1.29% of the portfolio, ranked #16.

Jackson Hole Capital Partners first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $8.18M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Jackson Hole Capital Partners held 35,906 shares of AbbVie worth $7.81M as of Q1 2026.
  • Jackson Hole Capital Partners bought 601 AbbVie shares in Q1 2026, an estimated $133K.
  • AbbVie made up 1.29% of Jackson Hole Capital Partners's portfolio in Q1 2026, its #16 holding.
  • Jackson Hole Capital Partners first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • Jackson Hole Capital Partners's AbbVie position peaked at $8.18M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Jackson Hole Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.